Fig. 1
From: The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer
Expression of ERα and NRF2 in PCa. A Box and whisker plots showing ERα and NRF2 mRNA expression in different PCa tissues from three publicly available datasets (t test). B Analysis of mean NRF2 mRNA expression in ERαHigh samples vs. ERαLow samples in prostate adenocarcinoma (PRAD) data from the Nelson dataset (t test). C The correlation of ERα and NRF2 expression in normal prostate and PRAD patients from TCGA (n (Normal) = 52), n (PRAD) = 498)) and GTEx (n (Normal) = 100) datasets. D The mRNA levels of ERα, NRF2 and AR in LNCaP, LNCaP abl, and PC3 cells are shown (one-way ANOVA). E Immunohistochemical analysis of ERα and NRF2 in normal prostate tissues (n = 21), PCa tumours with a low Gleason score (Gleason ≤ 6) (n = 17), PCa tumours with a high Gleason score (Gleason 8–10) (n = 17) and CRPC tissues (n = 28); representative microphotographs are shown; scale bar, 100 μm. The right panel shows the average optical density of ERα and NRF2 in normal prostate vs. low Gleason score vs. high Gleason score tissues and primary tumour vs. CRPC tissues (t test). The average optical density was measured with Image-Pro Plus 6.0 software; the values are presented as the means ± SEMs; *P < 0.05, **P < 0.01, ***P < 0.001